Skip to Content

Notice

Manufacturer of Controlled Substances; Notice of Application

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

Pursuant to section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on August 23, 2000, and December 5, 2000, Cerilliant Corporation, 14050 Summit Drive #121, P.O. Box 201088, Austin, Texas 78708-0189, made application by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

DrugSchedule
Cathinone (1235)I
Methcathinone (1237)I
N-Ethylamphetamine (1475)I
N,N-Dimethylamphetamine (1480)I
Aminorex (1585)I
4-Methylaminorex (cis isomer) (1590)I
Gamma hydroxybutyric acid (2010)I
Methaqualone (2565)I
Alpha-Ethyltryptamine (7249)I
Lysergic acid diethylamide (7315)I
Tetrahydrocannabinols (7370)I
Mescaline (7381)I
3,4,5-Trimethoxyamphetamine (7390)I
4-Bromo-2,5-dimethoxyamphetaime (7391)I
4-Bromo-2,5-dimethoxyphenethylamine (7392)I
4-Methyl-2,5-dimethoxyamphetamine (7395)I
2,5-Dimethoxyamphetamine (7396)I
2,5-Dimethoxy-4-ethylamphetamine (7399)I
3,4-Methylenedioxyamphetamine (7400)I
5-Methoxy-3,4-methylenedioxyamphetamine (7401)I
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)I
3,4-Methylenedioxy-N-ethylamphetamine (7404)I
3,4-Methylenedioxymethamphetamine (7405)I
4-Methoxyamphetamine (7411)I
Bufotenine (7433)I
Diethyltryptamine (7434)I
Dimethyltryptamine (7435)I
Psilocybin (7437)I
Psilocyn (7438)I
Acetyldihydrocodeine (9051)I
Benzylmorphine (9052)I
Codeine-N-oxide (9053)I
Dihydromorphine (9145)I
Heroin (9200)I
Morphine-N-oxide (9307)I
Normorphine (9313)I
Pholcodine (9314)I
Acetylmethadol (9601)I
Allyprodine (9602)I
Alphacetylmethadol except Levo-Alphacetylmethadol (9603)I
Alphameprodine (9604)I
Alphamethadol (9605)I
Betacetylmethadol (9607)I
Betameprodine (9608)I
Betamethadol (9609)I
Betaprodine (9611)I
Hydromorphinol (9627)I
Noracymethadol (9633)I
Norlevorphanol (9634)I
Normethadone (9635)I
Trimeperidine (9646)I
Para-Fluorofentanyl (9812)I
3-Methylfentanyl (9813)I
Alpha-methylfentanyl (9814)I
Acetyl-alpha-methylfentanyl (9815)I
Beta-hydroxyfentanyl (9830)I
Beta-hydroxy-3-methylfentanyl (9831)I
Start Printed Page 10321
Alpha-Methylthiofentanyl (9832)I
3-Methylthiofentanyl (9833)I
Thiofentanyl (9835)I
Amphetamine (1100)II
Methamphetamine (1105)II
Phenmetrazine (1631)II
Methylphenidate (1724)II
Amobarbital (2125)II
Pentobarbital (2270)II
Secobarbital (2315)II
Glutethimide (2550)II
Nabilone (7379)II
1-Phenylcyclohexylamine (7460)II
Phencyclidine (7471)II
1-Piperidinocyclohexanecarbonitrile (8603)II
Alphaprodine (9010)II
Cocaine (9041)II
Codeine (9050)II
Dihydrocodeine (9120)II
Oxycodone (9143)II
Hydromorphone (9150)II
Diphenoxylate (9170)II
Benzoylecgonine (9180)II
Ethylmorphine (9190)II
Hydrocodone (9193)II
Levomethorphan (9210)II
Levorphanol (9220)II
Isomethadone (9226)II
Meperidine (9230)II
Methadone (9250)II
Methadone-intermediate (9254)II
Morphine (9300)II
Thebaine (9333)II
Levo-alphacetylmethadol (9648)II
Oxymorphone (9652)II
Noroxymorphone (9668)II
Alfentanil (9737)II
Sufentanil (9740)II
Fentanyl (9801)II

The firm plans to manufacture small quantities of the listed controlled substances to make deuterated and non-deuterated drug reference standards which will be distributed to analytical and forensic laboratories for drug testing programs.

Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than April 16, 2001.

Start Signature

Dated: January 25, 2001.

Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

End Signature End Preamble

[FR Doc. 01-3752 Filed 2-13-01; 8:45 am]

BILLING CODE 4410-09-M